Rabbit anti-Human MYO1E Polyclonal Antibody | anti-MYO1E antibody
MYO1E, NT (MYO1E, MYO1C, Unconventional myosin-Ie, Myosin-Ic, Unconventional myosin 1E) (FITC)
FLISA: 1:1,000
Applications are based on unconjugated antibody.
NCBI and Uniprot Product Information
NCBI Description
This gene encodes a member of the nonmuscle class I myosins which are a subgroup of the unconventional myosin protein family. The unconventional myosin proteins function as actin-based molecular motors. Class I myosins are characterized by a head (motor) domain, a regulatory domain and a either a short or long tail domain. Among the class I myosins, this protein is distinguished by a long tail domain that is involved in crosslinking actin filaments. This protein localizes to the cytoplasm and may be involved in intracellular movement and membrane trafficking. Mutations in this gene are the cause of focal segmental glomerulosclerosis-6. This gene has been referred to as myosin IC in the literature but is distinct from the myosin IC gene located on chromosome 17. [provided by RefSeq, Jan 2012]
Uniprot Description
MYO1E: Myosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. Their highly divergent tails bind to membranous compartments, which are then moved relative to actin filaments. Binds to membranes containing anionic phospholipids via its tail domain. Required for normal morphology of the glomerular basement membrane, normal development of foot processes by kidney podocytes and normal kidney function. In dendritic cells, may control the movement of class II-containing cytoplasmic vesicles along the actin cytoskeleton by connecting them with the actin network via ARL14EP and ARL14. Defects in MYO1E are the cause of focal segmental glomerulosclerosis type 6 (FSGS6). A renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and progressive decline in renal function. Renal insufficiency often progresses to end-stage renal disease, a highly morbid state requiring either dialysis therapy or kidney transplantation. FSGS6 is a childhood-onset disorder resulting in nephrotic syndrome, which includes massive proteinuria, hypoalbuminemia, hyperlipidemia, and edema.
Protein type: Motor; Motility/polarity/chemotaxis; Actin-binding
Chromosomal Location of Human Ortholog: 15q21-q22
Cellular Component: actin cytoskeleton; adherens junction; brush border; clathrin-coated endocytic vesicle; cytoplasm; cytoskeleton; intercellular junction; myosin complex
Molecular Function: actin filament binding; ATP binding; ATPase activity, coupled; calmodulin binding; microfilament motor activity; motor activity; phosphoinositide binding; protein binding
Biological Process: actin filament-based movement; endocytosis; glomerular basement membrane development; glomerular filtration; in utero embryonic development; nitrogen compound metabolic process; platelet-derived growth factor receptor signaling pathway; post-embryonic hemopoiesis; vasculogenesis
Disease: Focal Segmental Glomerulosclerosis 6
Research Articles on MYO1E
Similar Products
Product Notes
The MYO1E myo1e (Catalog #AAA6323432) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The MYO1E, NT (MYO1E, MYO1C, Unconventional myosin-Ie, Myosin-Ic, Unconventional myosin 1E) (FITC) reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's MYO1E can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), FLISA. WB: 1:100-500 FLISA: 1:1,000 Applications are based on unconjugated antibody. Researchers should empirically determine the suitability of the MYO1E myo1e for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "MYO1E, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.